After leaving Endo Pharmaceuticals to lead a new research and development company, the former senior vice president of discovery and early development for the Malvern-based health solutions company received quite the parting gift: a deal to buy the rest of his drug discovery work.
Endo agreed to sell the platform, including several early-stage pharmaceutical candidates focused on oncology, pain and inflammation, to Dr. Sandeep Gupta’s freshly formed Asana BioSciences for an undisclosed amount, the Philadelphia Business Journal reported.
“The sale of the early-stage discovery platform is another step in the transformation of Endo,” President and CEO Rajiv De Silva said in the article. “We are committed to supporting the organic growth of our existing business segments as we search for attractive acquisition targets to enhance our portfolio of pharmaceutical products.”
Read more about the agreement in the Philadelphia Business Journal here.
